Skip to main content

Advertisement

SpringerLink
Log in

Interaction of PTPRO and TLR4 signaling in hepatocellular carcinoma

  • Research Article
  • Published:
Tumor Biology

Abstract

Protein tyrosine phosphatase receptor type O (PTPRO) has been identified as a tumor suppressor in a number of cancers including hepatocellular carcinoma (HCC). Toll-like receptor 4 (TLR4) plays diverse roles in HCC tumorigenesis and progression. The association between PTPRO and TLR4 signaling in HCC remains largely unknown. We aimed to clarify the interaction between PTPRO and TLR4 in HCC. Surprisingly, we found reduced and positive-related expression of TLR4 and PTPRO in 84 human HCC specimens. Increased TLR4 expression and activity was found in PTPRO-overexpressed HCC cells stimulated with lipopolysaccharide (LPS). The feedback regulation of PTPRO and TLR4 was dependent on nuclear factor-κB (NF-κB) activation, as suggested by NF-κB inhibition and luciferase reporter assay. Our study suggests that the effect of PTPRO on TLR4 signaling is dependent on NF-κB pathway, suggesting an interesting PTPRO/TLR4/NF-κB signaling feedback loop in HCC carcinogenesis and progression.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.

    Article  PubMed  Google Scholar 

  2. Sun B, Karin M. Inflammation and liver tumorigenesis. Front Med. 2013;7:242–54.

    Article  PubMed  Google Scholar 

  3. Kim DY, Han KH. Epidemiology and surveillance of hepatocellular carcinoma. Liver Cancer. 2012;1:2–14.

    Article  PubMed Central  Google Scholar 

  4. Szabo G, Dolganiuc A, Mandrekar P. Pattern recognition receptors: a contemporary view on liver diseases. Hepatology. 2006;44:287–98.

    Article  CAS  PubMed  Google Scholar 

  5. Matijevic T, Pavelic J. Toll-like receptors: cost or benefit for cancer? Curr Pharm Des. 2010;16:1081–90.

    Article  CAS  PubMed  Google Scholar 

  6. Yu LX, Yan HX, Liu Q, Yang W, Wu HP, Dong W, et al. Endotoxin accumulation prevents carcinogen-induced apoptosis and promotes liver tumorigenesis in rodents. Hepatology. 2010;52:1322–33.

    Article  CAS  PubMed  Google Scholar 

  7. Huang B, Zhao J, Unkeless JC, Feng ZH, Xiong H. TLR signaling by tumor and immune cells: a double-edged sword. Oncogene. 2008;27:218–24.

    Article  CAS  PubMed  Google Scholar 

  8. Naugler WE, Sakurai T, Kim S, Maeda S, Kim K, Elsharkawy AM, et al. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science. 2007;317:121–4.

    Article  CAS  PubMed  Google Scholar 

  9. Wang Z, Yan J, Lin H, Hua F, Wang X, Liu H, et al. Toll-like receptor 4 activity protects against hepatocellular tumorigenesis and progression by regulating expression of DNA repair protein Ku70 in mice. Hepatology. 2013;57:1869–81.

    Article  CAS  PubMed  Google Scholar 

  10. Hou J, Xu J, Jiang R, Wang Y, Chen C, Deng L, et al. Estrogen-sensitive PTPRO expression represses hepatocellular carcinoma progression by control of STAT3. Hepatology. 2013;57:678–88.

    Article  CAS  PubMed  Google Scholar 

  11. Motiwala T, Kutay H, Ghoshal K, Bai S, Seimiya H, Tsuruo T, et al. Protein tyrosine phosphatase receptor-type O (PTPRO) exhibits characteristics of a candidate tumor suppressor in human lung cancer. Proc Natl Acad Sci U S A. 2004;101:13844–9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  12. Huang YT, Li FF, Ke C, Li Z, Li ZT, Zou XF, et al. PTPRO promoter methylation is predictive of poorer outcome for HER2-positive breast cancer: indication for personalized therapy. J Transl Med. 2013;11:245.

    Article  PubMed Central  PubMed  Google Scholar 

  13. Fukata M, Abreu MT. Role of Toll-like receptors in gastrointestinal malignancies. Oncogene. 2008;27:234–43.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  14. Wei XQ, Guo YW, Liu JJ, Wen ZF, Yang SJ, Yao JL. The significance of toll-like receptor 4 (TLR4) expression in patients with chronic hepatitis B. Clin Invest Med. 2008;31:E123–30.

    CAS  PubMed  Google Scholar 

  15. Wang JP, Zhang Y, Wei X, Li J, Nan XP, Yu HT, et al. Circulating toll-like receptor (TLR) 2, TLR4, and regulatory T cells in patients with chronic hepatitis C. APMIS. 2010;118:261–70.

    Article  CAS  PubMed  Google Scholar 

  16. Machida K, Tsukamoto H, Mkrtchyan H, Duan L, Dynnyk A, Liu HM, et al. Toll-like receptor 4 mediates synergism between alcohol and HCV in hepatic oncogenesis involving stem cell marker Nanog. Proc Natl Acad Sci U S A. 2009;106:1548–53.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  17. Nishimura M, Naito S. Tissue-specific mRNA expression profiles of human toll-like receptors and related genes. Biol Pharm Bull. 2005;28:886–92.

    Article  CAS  PubMed  Google Scholar 

  18. Bauer AK, Dixon D, DeGraff LM, Cho HY, Walker CR, Malkinson AM, et al. Toll-like receptor 4 in butylated hydroxytoluene-induced mouse pulmonary inflammation and tumorigenesis. J Natl Cancer Inst. 2005;97:1778–81.

    Article  CAS  PubMed  Google Scholar 

  19. Mai CW, Kang YB, Pichika MR. Should a toll-like receptor 4 (TLR-4) agonist or antagonist be designed to treat cancer? TLR-4: its expression and effects in the ten most common cancers. Oncol Targets Ther. 2013;6:1573–87.

    CAS  Google Scholar 

  20. Dapito DH, Mencin A, Gwak GY, Pradere JP, Jang MK, Mederacke I, et al. Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. Cancer Cell. 2012;21:504–16.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  21. Alonso A, Sasin J, Bottini N, Friedberg I, Osterman A, Godzik A, et al. Protein tyrosine phosphatases in the human genome. Cell. 2004;117:699–711.

    Article  CAS  PubMed  Google Scholar 

  22. Motiwala T, Majumder S, Kutay H, Smith DS, Neuberg DS, Lucas DM, et al. Methylation and silencing of protein tyrosine phosphatase receptor type O in chronic lymphocytic leukemia. Clin Cancer Res. 2007;13:3174–81.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  23. Chen L, Juszczynski P, Takeyama K, Aguiar RC, Shipp MA. Protein tyrosine phosphatase receptor-type O truncated (PTPROt) regulates SYK phosphorylation, proximal B-cell-receptor signaling, and cellular proliferation. Blood. 2006;108:3428–33.

    Article  CAS  PubMed  Google Scholar 

  24. Calvisi DF, Ladu S, Gorden A, Farina M, Lee JS, Conner EA, et al. Mechanistic and prognostic significance of aberrant methylation in the molecular pathogenesis of human hepatocellular carcinoma. J Clin Invest. 2007;117:2713–22.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  25. Hou J, Xia Y, Jiang R, Chen D, Xu J, Deng L, et al. PTPRO plays a dual role in hepatic ischemia reperfusion injury through feedback activation of NF-kappaB. J Hepatol. 2014;60:306–12.

    Article  CAS  PubMed  Google Scholar 

  26. Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S, et al. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature. 2004;431:461–6.

    Article  CAS  PubMed  Google Scholar 

  27. Greten FR, Karin M. The IKK/NF-kappaB activation pathway-a target for prevention and treatment of cancer. Cancer Lett. 2004;206:193–9.

    Article  CAS  PubMed  Google Scholar 

  28. Myant KB, Cammareri P, McGhee EJ, Ridgway RA, Huels DJ, Cordero JB, et al. ROS production and NF-kappaB activation triggered by RAC1 facilitate WNT-driven intestinal stem cell proliferation and colorectal cancer initiation. Cell Stem Cell. 2013;12:761–73.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  29. Oltulu YM, Coskunpinar E, Ozkan G, Aynaci E, Yildiz P, Isbir T, et al. Investigation of NF-kappaB1 and NF-kappaBIA gene polymorphism in non-small cell lung cancer. Biomed Res Int. 2014;2014:530381.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  30. Li P, Gu J, Yang X, Cai H, Tao J, Lu Q, et al. Functional promoter -94 ins/del ATTG polymorphism in NFKB1 gene is associated with bladder cancer risk in a Chinese population. PLoS One. 2013;8:e71604.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  31. DiDonato JA, Mercurio F, Karin M. NF-kappaB and the link between inflammation and cancer. Immunol Rev. 2012;246:379–400.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

This work was supported by grants from the National Natural Science Foundation for Distinguished Young Scholars (81225017) and the National Natural Science Foundation (81072029 and 91029721). This work also supported in part by the program for Development of Innovative Research Team in the First Affiliated Hospital of NJMU and the Priority Academic Program of Jiangsu Higher Education Institutions.

Conflict of interest

None

Author information

Authors and Affiliations

  1. Department of Rheumatology, the First Affiliated Hospital, Nanjing Medical University, 210029, Nanjing, China

    Donghua Xu

  2. Liver Transplantation Center, the First Affiliated Hospital, Nanjing Medical University, 210002, Nanjing, China

    Donghua Xu, Xiaochen Wang, Shushan Yan, Yin Yin, Jiajie Hou, Xuehao Wang & Beicheng Sun

  3. State Key Laboratory of Reproductive Medicine, Nanjing Medical University, 210002, Nanjing, China

    Donghua Xu, Xiaochen Wang, Shushan Yan, Yin Yin, Jiajie Hou, Xuehao Wang & Beicheng Sun

  4. Key Laboratory of Living Donor Liver Transplantation, Ministry of Health, 210029, Nanjing, China

    Beicheng Sun

Authors
  1. Donghua Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xiaochen Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shushan Yan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yin Yin
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jiajie Hou
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Xuehao Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Beicheng Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Beicheng Sun.

Additional information

Donghua Xu, Xiaochen Wang and Shushan Yan equally contributed to this work.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Xu, D., Wang, X., Yan, S. et al. Interaction of PTPRO and TLR4 signaling in hepatocellular carcinoma. Tumor Biol. 35, 10267–10273 (2014). https://doi.org/10.1007/s13277-014-2302-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-014-2302-5

Keywords

Search

Navigation